Sellas Life Sciences Group Inc’s profitability metrics reveal strong financial health. The company currently boasts a gross margin of 39.66%. The profit margin, also known as the revenue ratio or ...

NEW YORK - SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), a biopharmaceutical company with a market capitalization of $81 million engaged in developing cancer therapies, has announced a registered ...

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) was the target of some unusual options trading activity on Monday. Traders bought 9,455 call options on the stock. This is an increase ...

SELLAS Life Sciences Group, Inc.’s SLS share price has dipped by 17.02%, which has investors questioning if this is right ...

Maxim Group analyst Jason McCarthy reiterated a Buy rating on SELLAS Life Sciences Group (SLS – Research Report) yesterday and set a price ...

1 Day SLS 35.15% DJIA 0.31% Russell 2K -0.66% Health ... Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares ...

SELLAS Life Sciences Group, Inc.’s SLS share price has surged by 21.80%, which has investors questioning if this is right time to sell.

CEO Michael Schiebe has acknowledged the slow sales of electric vehicles but remains firm on the company’s commitment to an all-electric future. As the original SLS Electric Drive units now ...

The EOS P3 NEXT is a midframe polymer SLS production system introduces new features for higher levels of productivity—as much as 50%.